Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
Authors:
Open Access
- 1 May 2018
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 1525-1531
Abstract
Purpose: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-analysis. Methods: We searched several databases for relevant articles. Prospective trials evaluating carfilzomib in RRMM patients with adequate data on cardiac toxicities were included for analysis. Pooled incidence, Peto ORs, and 95% CIs were calculated according to the heterogeneity of selected studies. Results: A total of 2,607 RRMM patients from eight prospective trials were included. The pooled incidence of all-grade congestive heart failure (CHF) and ischemic heart disease (IHD) related to carfilzomib in RRMM patients was 5.5% (95% CI: 4.3%–6.9%) and 2.7% (95% CI: 1.1%–6.7%), respectively. In addition, the use of carfilzomib significantly increased all-grade (Peto OR 2.33, 95% CI: 1.56–3.48, ppp=0.30) and high-grade (Peto OR 1.41, 95% CI: 0.73–2.72, p=0.31) IHD in RRMM patients receiving carfilzomib. Conclusion: The use of carfilzomib in RRMM patients significantly increases the risk of developing CHF but not IHD. Clinicians should be cautious about the risk of CHF associated with carfilzomib to maximize the benefits and minimize the toxicities.Keywords
This publication has 28 references indexed in Scilit:
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia, 2013
- Cardiotoxicity of the Anticancer Therapeutic Agent BortezomibThe American Journal of Pathology, 2010
- Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)Oncogene, 2009
- Characterization of the ubiquitin–proteasome system in bortezomib-adapted cellsLeukemia, 2009
- Dysregulation of the Ubiquitin-Proteasome System in Human Carotid AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Effect of Acetylsalicylic Acid on Nuclear Factor-κB Activation and on Late Preconditioning Against Infarction in the MyocardiumJournal of Cardiovascular Pharmacology, 2005
- Increased Proteasome Activity, Ubiquitin-Conjugating Enzymes, and eEF1A Translation Factor Detected in Breast Cancer TissueCancer Research, 2005
- BortezomibNature Reviews Drug Discovery, 2003
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985